In parallel, several tau aggregation inhibitors tested have failed in clinical trials due to either unwanted side effects or lack of efficacy, e.g. RemberTM in Phase II [62, 63] (NCT00684944; NCT00515333), and TRx0237 (LMTM) in three Phase III trials of patients with mild-to-moderate AD and behavioral variant frontotemporal dementia [64] (NCT01689246; NCT01689233; NCT02245568). The gene discussed is MAPT; the disease is Alzheimer disease.